Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report.

Muhannad Abdulrahman Alsemari Hakeam A HakeamHussain AlsalmanTarek Amin

Published in: Therapeutic advances in infectious disease (2020)

High-dose tigecycline therapy is gaining wide acceptance in treating infections caused by multidrug-resistant bacteria. There are no reports of cutaneous hyperpigmentation with the use of high-dose tigecycline. Here we report a case of a woman who developed reversible cutaneous hyperpigmentation within 48 h of receiving high-dose tigecycline.

Keyphrases

high dose
acinetobacter baumannii
multidrug resistant
klebsiella pneumoniae
low dose
stem cell transplantation
drug resistant
pseudomonas aeruginosa
gram negative
escherichia coli
stem cells
cystic fibrosis